Court Sets Aside R15.5-Billion South Africa ARV Tender
The High Court ordered a fresh tender process following procurement irregularities at the Department of Health.
Updated on Oct. 22, 2026 in Healthcare
Live Poll
Should the government prioritize strict procurement competition rules even if it risks disrupting essential supply chains?
The High Court has declared the R15.5-billion antiretroviral (ARV) tender awards unlawful and unconstitutional due to procurement irregularities. The Department of Health must now reconsider the tender process within 120 days.
Why it matters
The ruling addresses significant failures in tender adjudication, including the department's oversight regarding bid collusion suspicions and unsubstantiated ownership claims. This intervention aims to restore integrity to a critical national drug supply programme.
The tender is valued at R15.5-billion, with R12.6-billion specifically allocated for fixed-dose combinations. Current suppliers are required to maintain drug deliveries to avoid shortages while the Department of Health re-evaluates the awards.
The players
Department of Health
The South African government body responsible for national health policy, hospital administration, and the procurement of essential medicines.
Graham Girdwood
An Acting Judge of the High Court who presided over the case and delivered the judgment regarding procurement irregularities.
Innovata
A pharmaceutical entity implicated in the tender dispute that faces exclusion from the reconsideration process due to licensing failures.
Viatris
A global pharmaceutical company named in the court order regarding the lack of valid manufacturing site licenses at bid closure.
Barrs
A pharmaceutical supplier cited by the court in connection to potential bid collusion investigations with Innovata.
The details
Acting Judge Graham Girdwood ruled that Innovata and Viatris lacked valid manufacturing site licenses at the time of bid closure, leading to their exclusion from the upcoming reconsideration process. Furthermore, the court has ordered an adjustment of scoring metrics for Innovata and Barrs regarding claims related to historically disadvantaged individuals.
Timeline
December 2025: The original ARV tender programme came into effect.
22 October 2026: The High Court handed down the ruling against the department.
Within 120 days of 22 October 2026: The Department of Health must reconsider the tender awards.
90 days after new awards: The formal setting-aside of the current awards will take effect.
Market Landscape
This judicial intervention reflects a broader effort to ensure transparency and accountability in public sector procurement processes. By enforcing compliance, the court decision signals a shift towards tighter regulatory oversight for companies seeking government contracts.
Patients will continue to receive their medication without interruption, as current suppliers are mandated to maintain deliveries throughout the transition. The ruling ensures that future supply chains for critical drugs will be managed through a corrected and more transparent procurement framework.
The takeaway
Maintaining steady drug supply chains remains the priority during the 120-day reconsideration window for tender awards. Patients should continue their treatment routines as per existing arrangements while the government resolves these procedural matters.
What happens next
The Department of Health is required to finalise the new tender awards within 120 days of the 22 October 2026 ruling.
Further reading
For more information on national health procurement, visit the South Africa Healthcare section.
Live Poll
Should the government prioritize strict procurement competition rules even if it risks disrupting essential supply chains?
